Quantification of Integrin β3–Positive Areas in A-431 and FaDu Tumors
| A-431, β3 integrin area (%) | FaDu, β3 integrin area (%) | |||
| Day | Control (n = 3) | Bevacizumab (n = 3) | Control (n = 3) | Bevacizumab (n = 3) |
| 7 | 5.79 ± 0.67 | 2.50 ± 0.41* | 5.43 ± 0.27 | 4.20 ± 0.77 |
| 14 | 5.20 ± 0.85 | 2.52 ± 0.35* | 5.16 ± 0.17 | 4.69 ± 1.02 |
* P < 0.005 for treated vs. control tumors.
Value for each tumor was calculated as mean of positive areas in 6 different regions of section, stained for β3 integrin.